Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Depreciation & Amortization · Q3 FY2026 · quarter ended Jan 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $1.98M rose 5.0% year over year, ahead of the -14.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 16.4% from the prior quarter.
Context
- Depreciation & amortization amounted to 13.3% of revenue in FY2025, down 28.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.0% holds above the trailing-twelve-month pace of -14.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 7.97M USD
- Year-over-year change
- -31.1%
- 5-year CAGR
- +75.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 7.97M | -31.1% |
| FY2024 | 2024-04-30 | 11.56M | +138.1% |
| FY2023 | 2023-04-30 | 4.86M | — |
| FY2021 | 2021-04-30 | 420K | -12.1% |
| FY2020 | 2020-04-30 | 478K | — |
Depreciation & Amortization vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's LTM Jan 2026 depreciation & amortization of $8.22M is the 2nd largest of the 3 companies compared; the peer median is $10.43M.
- Its year-over-year change of -14.7% is the 2nd highest of 3, against a peer median of -4.1%.
- Depreciation & amortization amounts to 9.8% of revenue for KMTS, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $20.08M | -23.8% | +10.5% | 2.4% | |
| LTM Jan 2026 | $8.22M | -14.7% | — | 9.8% | |
| LTM Mar 2026 | $777K | +15.6% | +22.4% | 1.3% | |
| Peer median (excluding KMTS) | $10.43M | -4.1% | +16.5% | 1.8% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | (29.47M) | (34.1M) | (84.24M) | (94.12M) | (113.81M) |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M |
| Deferred Income Tax | 0 | 0 | (45K) | 12K | 64K |
| Stock-Based Compensation | 0 | 1.86M | 1.21M | 1.49M | 24.27M |
| Change in Working Capital | (2.01M) | (19K) | 1.3M | 4.39M | (6.2M) |
| Accounts Receivables | 0 | 0 | 0 | (2M) | (8.78M) |
| Inventory | 0 | 0 | (733K) | (1.18M) | (3.44M) |
| Accounts Payables | (790K) | (132K) | 2.14M | 7.34M | 2.84M |
| Other Working Capital | (1.22M) | 113K | (112K) | 223K | 3.18M |
| Other Non-Cash Items | 706K | 1.94M | 7.28M | 4.44M | 10.11M |
| Operating Cash Flow | (30.29M) | (29.9M) | (69.64M) | (72.24M) | (77.61M) |
| Capital Expenditures | (232K) | (336K) | (15.46M) | (12.51M) | (23.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 2K | 0 | 285K | 283K |
| Investing Cash Flow | (232K) | (334K) | (15.46M) | (12.23M) | (23.31M) |
| Debt Repayment | 0 | 20M | (5.33M) | 5.88M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 215.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (183K) | (187K) | (671K) | (799K) | (1.65M) |
| Other Financing Activities | 30.42M | 29M | 0 | (2.35M) | 12.73M |
| Financing Cash Flow | 30.24M | 48.82M | 96.11M | 77.73M | 330.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (286K) | 18.59M | 11M | (6.74M) | 229.35M |
| Free Cash Flow | (30.53M) | (30.23M) | (85.1M) | (84.75M) | (101.2M) |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.